Brief: Werewolf Therapeutics Receives Fast Track Designation From The U.S. FDA For WTX-124, An Investigational Therapy For The Treatment Of Cancer
08/10/2025 13:08
Oct 8 (Reuters) - Werewolf Therapeutics Inc HOWL.O: WEREWOLF THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM THE U.S. FDA FOR WTX-124, AN INVESTIGATIONAL THERAPY FOR THE TREATMENT OF CANCER WEREWOLF THERAPEUTICS INC: ANTICIPATE SHARING PRELIMINARY DATA FROM ONGOING WTX-124 PHASE 1/1B CLINICAL TRIAL IN Q4 Source text: ID:nGNX87hsNk Further company coverage: HOWL.O ((Reuters.Briefs@thomsonreuters.com;))